AbbVie Gets Humira Patent Invalidated As Obvious

Law360, New York (June 26, 2013, 6:32 PM EDT) -- AbbVie Inc. has won a ruling in New York federal court declaring invalid a patent for the anti-inflammatory drug Humira held by the Mathilda and Terence Kennedy Institute of Rheumatology Trust, meaning the drugmaker no longer will have to pay the trust licensing fees.

U.S. District Judge Paul A. Crotty ruled June 20 that the trust's U.S. Patent Number 7,846,442, which covers the cocktail of ingredients that make up Humira, was invalid for obviousness-type double patenting. Judge Crotty presided over the four-day bench trial last fall....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.